Abstract
We investigated the schedule dependency of G-CSF (10 μg/kg) alone in mobilizing peripheral blood progenitor cells (PBPC) in breast cancer patients. After a median of three cycles (range, 2–6) of anthracycline-based chemotherapy, 49 patients with breast cancer (stage II/III, ⩾10+ Ln n = 36; locally advanced/ inflammatory n = 8, stage IV (NED) n = 5) underwent PBPC collection after steady-state mobilization either with 1 × 10 μg/kg (n = 27) or with 2 × 5 μg/kg (n = 22) G-CSF daily for 4 consecutive days until completion of apheresis. Apheresis was started on day 5. Priming with 2 × 5 μg/kg resulted in a higher median number of CD34+ cells (5.8 vs 1.9 × 106/kg, P = 0.003), MNC (6.6 vs 2.6 × 108/kg, P < 0.001) and cfu-gm (6.5 vs 1.3 × 104/kg, P = 0.001) in the first apheresis than with 1 × 10 μg/kg. Also the overall number of collected BFU-E was higher in the 2 × 5 μg group (9.2 vs 3.1 × 104/kg; P = 0.01). After high-dose chemotherapy with cyclophosphamide/thiotepa/mitoxantrone (n = 46) hematopoietic engraftment with leukocyte count >1.0/nl was reached in both groups after a median of 10 days (range, 8–15) and with platelets count >50/nl after 12 (range, 9–40) and 13 days (range, 12–41), respectively. A threshold of >2.5 × 106/kg reinfused CD34+ cells ensured rapid platelet engraftment (12 vs 17 days; P = 0.12). Therefore, the target of collecting >2.5 × 106 CD34+ cells was achieved in 21/27 (80%) patients of the 1 × 10 μg group and in 21/22 (95%) patients of the 2 × 5 μg/kg group with a median of two aphereses (range, 1–4). None in the 10 μg/kg group, but 6/22 (28%) patients in the 2 × 5 μg/kg group required only one apheresis procedure, resulting in fewer apheresis procedures in the 2 × 5 μg/kg group (mean, 1.8 vs 2.3, P = 0.01). These results demonstrate that priming with 10 μg/kg G-CSF alone is well tolerated and effective in mobilizing sufficient numbers of CD34+ cells in breast cancer patients and provide prompt engraftment after CTM high-dose chemotherapy. G-CSF given 5 μg/kg twice daily (2 × 5 μg) leads to a higher harvest of CD34+ cells and required fewer apheresis procedures than when given 10 μg/kg once daily (1 × 10 μg).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kröger, N., Zeller, W., Hassan, H. et al. Stem cell mobilization with G-CSF alone in breast cancer patients: higher progenitor cell yield by delivering divided doses (2 × 5 μg/kg) compared to a single dose (1 × 10 μg/kg). Bone Marrow Transplant 23, 125–129 (1999). https://doi.org/10.1038/sj.bmt.1701549
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1701549
Keywords
This article is cited by
-
Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers—results of a dose escalation trial
Journal of Translational Medicine (2017)
-
Prospective randomized comparative observation of single- vs split-dose lenograstim to mobilize peripheral blood progenitor cells following chemotherapy in patients with multiple myeloma or non-Hodgkin’s lymphoma
Annals of Hematology (2005)
-
Cytokines alone for PBPC collection in patients with advanced gynaecological malignancies: G-CSF vs G-CSF plus EPO
Bone Marrow Transplantation (2004)
-
A randomised study of 10 μg/kg/day (single dose) vs 2 × 5 μg/kg/day (split dose) G-CSF as stem cell mobilisation regimen in high-risk breast cancer patients
Bone Marrow Transplantation (2003)
-
Granulocyte colony-stimulating factor alone at 12 μg/kg twice a day for 4 days for peripheral blood progenitor cell priming in pediatric patients
Bone Marrow Transplantation (2002)